10-K: DiaMedica Therapeutics Reports FY 2024 Results, Highlights DM199 Clinical Programs in Stroke and Preeclampsia

DiaMedica Therapeutics focuses on advancing its DM199 clinical programs for acute ischemic stroke and preeclampsia, with key milestones expected in 2025.

Summary

• DiaMedica Therapeutics is a clinical-stage biopharmaceutical company focusing on severe ischemic diseases, primarily acute ischemic stroke (AIS) and preeclampsia (PE).
• The company's lead candidate, DM199, is a recombinant form of human tissue kallikrein-1 (rhKLK1) and has received Fast Track designation from the FDA for AIS treatment.
• A Phase 2/3 ReMEDy2 clinical trial is underway for DM199 in AIS, with an adaptive design intended to enroll approximately 300 participants globally and an interim analysis after the first 200 participants.
• A Phase 2 investigator-sponsored trial is ongoing for DM199 in PE, with initial results expected in the second quarter of 2025.
• The company's strategy includes completing clinical site activation and enrollment for the ReMEDy2 trial, advancing the PE trial, continuing manufacturing process development, and identifying strategic partners.
• As of December 31, 2024, DiaMedica had $44.1 million in cash, cash equivalents, and marketable securities, which are expected to fund operations for at least the next 12 months.
• The company reported a net loss of $24.4 million for the year ended December 31, 2024, compared to a net loss of $19.4 million for the previous year.

Sentiment

Score: 5

Explanation: The document presents a balanced view, highlighting both the potential of DM199 and the challenges faced by the company. The financial results indicate ongoing losses, but the company has sufficient cash for the next 12 months. The sentiment is neutral, reflecting the inherent risks and uncertainties in the biopharmaceutical industry.

Positives

• DM199 has Fast Track designation from the FDA, potentially expediting the approval process.
• The company has completed studies on fertility, embryofetal development, and preand post-natal development in animal models, which support the potential safety in pregnant humans.
• The company is expanding its ReMEDy2 trial globally to Canada, Australia, and Georgia.
• The company has expanded its internal clinical team and brought in-house certain trial activities, including site identification, qualification and activation, clinical site monitoring and overall program management.

Negatives

• The company has experienced slower than expected site activations and enrollment in its ReMEDy2 trial.
• The company has incurred significant operating losses in every reporting period since its inception and expects to continue to incur such losses.
• The company is dependent on the success of DM199 and may not be able to successfully obtain regulatory or marketing approval for, or successfully commercialize, this product candidate.

Risks

• Difficulty enrolling patients in the ReMEDy2 trial could delay or jeopardize the trial.
• The adaptive design of the ReMEDy2 trial could require enrolling more patients, increasing costs and time.
• Clinical trials may be suspended or terminated if not conducted according to regulatory requirements or if results are negative.
• The company relies on third parties for clinical trials and manufacturing, which could cause delays or quality issues.
• The company may need additional funding, which may not be available on acceptable terms.
• The company faces competition from other biotechnology and pharmaceutical companies.
• The company's common share price has been volatile and may continue to be volatile.

Future Outlook

The company expects to continue its Phase 2/3 trial in patients with AIS, the PE trial, and to otherwise fund its planned operations for at least the next 12 months from the date of issuance of the financial statements included in this report. The company anticipates that its quarterly expenses will increase moderately relative to recent prior periods as it expands its ReMEDy2 trial globally and continues site activation and enrollment and as it expands its DM199 clinical development program into PE.

Industry Context

The biopharmaceutical industry is highly competitive, with numerous companies pursuing treatments for AIS and PE. DiaMedica faces competition from established pharmaceutical companies and smaller biotechnology firms, some of which have greater resources. The company believes its DM199 product candidate, development capabilities, experience and scientific knowledge provide it with certain competitive advantages.

Comparison to Industry Standards

• The document mentions tPA (Activase) as the current standard pharmaceutical treatment for AIS, highlighting its limitations in therapeutic window and risk of hemorrhages.
• The document references Kailikang, a human urine-derived KLK1 approved in China, and porcine KLK1 approved in Japan, China, and South Korea, as existing KLK1 therapies for AIS and hypertension.
• The document mentions Metformin, an established treatment for type 2 diabetes, being studied in late-stage clinical trials for preeclampsia in South Africa and Sweden.
• The document mentions CBP-4888, a short interfering RNA (siRNA) targeting sFlt-1, being developed by Comanche Biopharma for preeclampsia.

Management Changes

Legal Proceedings

• The company is involved in ongoing litigation with Pharmaceutical Research Associates Group B.V. (PRA Netherlands) related to a clinical research agreement.
• The NCC has issued a decision to consolidate both appeals and evaluate them concurrently at a single hearing currently scheduled for March 20, 2025.

Stakeholder Impact

• Shareholders face potential dilution from future equity issuances.
• Patients with AIS and PE could benefit from successful development and approval of DM199.
• Employees face potential changes in compensation and benefits.
• The company's financial stability affects its ability to meet obligations to suppliers and creditors.

Next Steps

• Complete activation of up to 100 global clinical sites and enroll participants in the ReMEDy2 Phase 2/3 trial.
• Complete Part 1A and then Part 1B of the Phase 2 IST for PE.
• Engage the FDA regarding the PE development program; file an IND; submit applications for Fast Track and/or Breakthrough designations; and initiate a new, global Phase 2 trial.
• Continue manufacturing process development to support anticipated applications for commercial approval of DM199.
• Identify a strategic partner(s) to assist with future clinical development and commercialization of DM199.

Key Dates